Health experts warn of MASLD risks and alcohol-related hypoglycemia

Medical experts are highlighting the importance of monitoring liver health and blood sugar stability, particularly regarding metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes management.

MASLD, formerly known as non-alcoholic fatty liver disease, affects approximately one in three adults. While often asymptomatic, it can progress to inflammation (MASH) and liver fibrosis, potentially leading to cirrhosis or liver cancer. Experts emphasize that assessing the degree of fibrosis is more critical for long-term prognosis than simply measuring fat volume. Recent developments include the FDA's approval of Semaglutide for patients with MASH and moderate fibrosis (F2–F3).

Separately, healthcare providers warn diabetes patients about the risks of alcohol consumption. Alcohol can inhibit glucose production in the liver, leading to dangerous hypoglycemia. Symptoms such as cold sweats, dizziness, and tremors are often mistaken for simple hangovers, but they may indicate critically low blood sugar. Patients using insulin or sulfonylureas are at particularly high risk and should monitor blood sugar levels closely after drinking.